HOUSTON, Dec. 17, 2019 /PRNewswire/ — CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (“CNS” or the “Company”), a biotechnology company specializing in the development of novel treatments for brain tumors, today announced the completed good...
TAIPEI, Taiwan, Dec. 18, 2019 /PRNewswire/ — OBI Pharma, a Taiwan biopharma company (TPEx: 4174), today announced the initiation of a Phase 1/2 clinical trial (ClinicalTrials.gov Identifier: NCT04084366) of OBI-999, an antibody drug conjugate (ADC) targeting...
LUND, Sweden, Dec. 18, 2019 /PRNewswire/ — BioInvent International AB (“BioInvent” or the “Company”) (OMXS: BINV) today announces that it has entered into a clinical trial collaboration and supply agreement with MSD, a tradename of Merck...
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biotechnology company, today announced dosing of the first patient in its REDUX Phase II study of DM199 for the treatment of Chronic Kidney Disease (CKD). This study is designed to investigate the safety,...
NEWTON, Mass., Dec. 16, 2019 (GLOBE NEWSWIRE) — Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases with significant unmet...
First allogeneic, off-the-shelf cell therapy approach that enhances T-cell activation through localized OX40-mediated co-stimulation of dormant immune signals Heat Biologics, Inc. (NASDAQ: HTBX), a clinical-stage biopharmaceutical company specialized in the...
Email
Text